Pliant Therapeutics develops drugs to treat fibrotic diseases. The company focuses on inhibiting integrin pathways involved in tissue scarring to stop disease progression and potentially restore normal organ function. Its products work by targeting fibrosis-related mechanisms at the molecular level, guided by medicinal chemistry and advanced screening technologies, and advancing candidates through clinical trials toward commercialization. Pliant differentiates itself through deep expertise in integrin biology and fibrosis, aiming to create best-in-class therapies that can address multiple fibrotic indications and provide targeted, effective treatments. The company’s goal is to transform the treatment of fibrotic diseases by halting progression and reversing fibrosis, improving patient outcomes and organ function.
Company Size
51-200
Company Stage
IPO
Headquarters
South San Francisco, California
Founded
2015
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?